Prothena Corporation PLC (NASDAQ:PRTA)
| 77.40 Delayed Data As of 4:14pm ET |  +2.09 / +2.78%Today’s Change | 9.67 Today|||52-Week Range 79.75 | +544.46% Year-to-Date |
Latest PRTA News | Press Releases
| VRTX vs. PRTA: Which Stock Should Value Investors Buy Now? Sep 23 / Zacks.com - Paid Partner Content | With Prothena Up Over 500% This Year, Is It Too Late to Get in? Sep 18 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 75.31 |
| Today’s open | 75.60 |
| Day’s range | 75.45 - 79.71 |
| Volume | 11,474 |
| Average volume (3 months) | 464,469 |
| Market cap | $3.4B |
Data as of 4:14pm ET, 09/27/2021
Growth & Valuation
| Earnings growth (last year) | -42.96% |
| Earnings growth (this year) | +141.16% |
| Earnings growth (next 5 years) | -5.67% |
| Revenue growth (last year) | +4.79% |
| P/E ratio | NM |
| Price/Sales | 561.99 |
| Price/Book | 16.36 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NKTRNektar Therapeutics | +0.32 | +1.73% |
| ALLOAllogene Therapeutic... | +0.09 | +0.35% |
| AUPHAurinia Pharmaceutic... | +0.34 | +1.46% |
| IOVAIovance Biotherapeut... | +0.36 | +1.44% |
Data as of 4:17pm ET, 09/27/2021
Financials
| Next reporting date | November 9, 2021 |
| EPS forecast (this quarter) | $1.88 |
| Annual revenue (last year) | $853.0K |
| Annual profit (last year) | -$111.1M |
| Net profit margin | -13,029.78% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Dun Laoghaire, Dublin |
Forecasts
